Quick Answer
Dermata Therapeutics, Inc. reported Operating Income of -$7.77 million for fiscal year 2025.
Dermata Therapeutics, Inc. Operating Income — Annual History
| Fiscal Year | Operating Income | YoY Change |
|---|---|---|
| 2025 | -$7.77M | +37.9% |
| 2024 | -$12.51M | -55.6% |
| 2023 | -$8.04M | +16.9% |
| 2022 | -$9.67M | -23.1% |
| 2021 | -$7.86M | -147.6% |
| 2020 | -$3.17M | — |
Quarterly Operating Income
| Quarter Ending | Operating Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$1.76M | +45.4% | +0.7% |
| June 30, 2025 | -$1.77M | +38.5% | +24.2% |
| March 31, 2025 | -$2.34M | +27.0% | +27.5% |
| September 30, 2024 | -$3.23M | -78.0% | -11.9% |
| June 30, 2024 | -$2.88M | -66.5% | +10.0% |
| March 31, 2024 | -$3.20M | -40.7% | -76.8% |
| September 30, 2023 | -$1.81M | +25.9% | -4.6% |
| June 30, 2023 | -$1.73M | +36.6% | +23.9% |
- Dermata Therapeutics, Inc. showed an increase of +37.9% in Operating Income compared to the prior fiscal year.
- Over the 2020–2025 period, Dermata Therapeutics, Inc.’s operating income has declined by 145.0% (from -$3.17 million to -$7.77 million).
- The most recent figure is from Dermata Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 26, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: